Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Aaron W Michels"'
Autor:
Kimber M Simmons, Aimon K Alkanani, Kristen A McDaniel, Christopher Goyne, Dongmei Miao, Zhiyuan Zhao, Liping Yu, Aaron W Michels
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0166213 (2016)
Type 1 diabetes (T1D) is increasing in incidence and predictable with measurement of serum islet autoantibodies (iAb) years prior to clinical disease onset. Identifying iAb positive individuals reduces diabetic ketoacidosis and identifies individuals
Externí odkaz:
https://doaj.org/article/e59640b3b6ed4ecdbd18a76a32be96cb
Autor:
Angela M. Mitchell, Erin E. Baschal, Kristen A. McDaniel, Kimber M. Simmons, Laura Pyle, Kathleen Waugh, Andrea K. Steck, Liping Yu, Peter A. Gottlieb, Marian J. Rewers, Maki Nakayama, Aaron W. Michels
Publikováno v:
JCI Insight, Vol 7, Iss 18 (2022)
T cell receptor (TCR) sequences are exceptionally diverse and can now be comprehensively measured with next-generation sequencing technologies. However, a thorough investigation of longitudinal TCR repertoires throughout childhood in health and durin
Externí odkaz:
https://doaj.org/article/fdd60e79e23f4d1292274bdb7907007f
Autor:
Laurie G. Landry, Amanda M. Anderson, Holger A. Russ, Liping Yu, Sally C. Kent, Mark A. Atkinson, Clayton E. Mathews, Aaron W. Michels, Maki Nakayama
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Proinsulin is an abundant protein that is selectively expressed by pancreatic beta cells and has been a focus for development of antigen-specific immunotherapies for type 1 diabetes (T1D). In this study, we sought to comprehensively evaluate reactivi
Externí odkaz:
https://doaj.org/article/a91cd3ee2151464383c8205ba8eb1435
Publikováno v:
Diabetes Technology & Therapeutics.
Autor:
KIMBER M. SIMMONS, TIMOTHY B. VIGERS, LAURA PYLE, ERIN M. YOUNGKIN, ERIN E. BASCHAL, KRISTEN MCDANIEL, LIPING YU, AARON W. MICHELS
Publikováno v:
Diabetes. 71
The incidence of type 1 diabetes continues to increase, most notably in American Hispanic (HIS) youth. Type 1 diabetes autoimmunity has not been fully characterized in HIS youth. Determining the prevalence of islet autoantibody positivity in HIS yout
Autor:
ANGELA M. MITCHELL, ERIN E. BASCHAL, KRISTEN MCDANIEL, LAURA PYLE, KATHLEEN WAUGH, ANDREA STECK, LIPING YU, PETER GOTTLIEB, MARIAN REWERS, MAKI NAKAYAMA, AARON W. MICHELS
Publikováno v:
Diabetes. 71
In type 1 diabetes (T1D) , T cells target and destroy pancreatic beta cells. T cells express T cell receptors (TCRs) which recognize peptide antigens, and each TCR is unique to a given T cell. To understand the TCR repertoire during T1D development,
Autor:
JULIA Q. MATUSCHEK, HOLGER A. RUSS, TAYLOR M. TRIOLO, AARON W. MICHELS, KRISTEN MCDANIEL, MARIA S. HANSEN, SHANE WILLIAMS, ROBERTO CASTRO-GUTIERREZ, ALI SHILLEH
Publikováno v:
Diabetes. 71
Type 1 diabetes (T1D) is an autoimmune disease marked by permanent loss of insulin-producing pancreatic β cells. Genome wide association studies have identified protein tyrosine non receptor type 2 (PTPN2) as a high-risk T1D gene. PTPN2 has been cla
Publikováno v:
Diabetes. 71
Background: Insulinoma antigen-2 (IA2) is a major self-antigen in T1D with post translational modification (PTM) of the extracellular domain (IA2ec) by deamidation eliciting T cell responses in T1D patients. Yet the autoantibodies (Abs) to these IA2e
Autor:
Taylor K. Armstrong, Kimber M. Simmons, Angela M. Mitchell, Aimon A. Alkanani, Erin E. Baschal, Kristen A. McDaniel, Liping Yu, Aaron W. Michels, Laura Pyle
Publikováno v:
Diabetes. 69:1763-1769
Certain HLA class II genes increase the risk for type 1 diabetes (T1D) development while others provide protection from disease development. HLA class II alleles encode MHC proteins on antigen-presenting cells, which function to present peptides and
Autor:
Halis Kaan, Akturk, Kasey L, Couts, Erin E, Baschal, Kagan E, Karakus, Robert J, Van Gulick, Jacqueline A, Turner, Laura, Pyle, William A, Robinson, Aaron W, Michels
Publikováno v:
JAMA Network Open. 5:e2246400
ImportanceTreatment with immune checkpoint inhibitors (ICIs) has increased survival in patients with advanced malignant melanoma but can be associated with a wide range of immune-related adverse events (irAEs). The role of human leukocyte antigen (HL